Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the impact of infant respiratory syncytial virus on (1) paediatric intensive care bed capacity, (2) NHS elective care capacity, (3) GP visits, and (4) economic productivity.

NHS England has not made specific assessments of the impact of infant respiratory syncytial virus (RSV) on paediatric intensive care bed capacity, National Health Service elective care capacity, and general practice visits, as RSV is often accompanied by other respiratory viruses and bacterial infections, and it is therefore difficult to measure the exact contribution of RSV. Neither has the Department assessed the wider productivity and economic benefits of RSV specifically.

The NHS plans for a wide range of scenarios ahead of each winter, and will continue to adapt plans based on respiratory infections surveillance, including RSV, and NHS activity data. This includes specialised commissioning led winter surge planning for paediatric critical care, as well as wider winter planning. For RSV specifically, this includes the annual immunisation programme, which continues to be managed and reviewed in accordance with advice from the Joint Committee on Vaccination and Immunisation (JCVI). For 2024 to 2025, preparedness may include rolling out a new RSV vaccination programme following the JCVI’s recommendations issued in September 2023, subject to approval from the Department.

The health impact of infant RSV was assessed in a scientific paper published in Lancet Regional Health Europe in January 2024, and has been assessed previously in scientific papers published by Public Health England and others. This work contributed to the JCVI’s assessment of RSV’s impact, and advice to implement an immunisation programme to prevent infant RSV.